Impact of metformin use on the outcomes of newly diagnosed diffuse large B‐cell lymphoma and follicular lymphoma
出版年份 2019 全文链接
标题
Impact of metformin use on the outcomes of newly diagnosed diffuse large B‐cell lymphoma and follicular lymphoma
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-05-28
DOI
10.1111/bjh.15997
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
- (2018) Danxia Chu et al. BMC CANCER
- Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis
- (2018) Grace H. Tang et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
- (2018) Angelo Cignarelli et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Epidemiological dimensions of the association between type 2 diabetes and cancer: A review of observational studies
- (2018) Carlotta Sacerdote et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Metformin in cancer
- (2018) Ritwika Mallik et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients
- (2018) Jiao Hu et al. MEDICINE
- Metformin as an Anticancer Agent
- (2018) Ales Vancura et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment
- (2018) Min Li et al. Frontiers in Physiology
- Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study
- (2017) James R Cerhan et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma
- (2017) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways
- (2017) Shoeb Ikhlas et al. LIFE SCIENCES
- High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
- (2017) T E Witzig et al. Blood Cancer Journal
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
- (2016) Gilles Salles et al. HAEMATOLOGICA
- Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
- (2016) Gadi Shlomai et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study
- (2016) Yaser Alkhatib et al. LEUKEMIA & LYMPHOMA
- PI3K signaling pathway in normal B cells and indolent B-cell malignancies
- (2016) Georgios Pongas et al. SEMINARS IN ONCOLOGY
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
- (2016) Gilles Salles et al. HAEMATOLOGICA
- Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial
- (2016) Patrick B Johnston et al. Lancet Haematology
- Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study
- (2015) Su-Hsin Chang et al. Lancet Haematology
- The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma
- (2014) W Wu et al. BRITISH JOURNAL OF CANCER
- Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
- (2014) S. Gandini et al. Cancer Prevention Research
- Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
- (2014) Zheng Wang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
- (2014) Agata Majchrzak et al. MOLECULES
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy
- (2012) W-Y Shi et al. Cell Death & Disease
- Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma
- (2011) Yu Xuan Koo et al. LEUKEMIA & LYMPHOMA
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- (2010) Kensei Tobinai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started